GlaxoSmithKline Pakistan (KAR:GLAXO) EPS (Basic): ₨33.01 (TTM As of Mar. 2026)


KAR:GLAXO GlaxoSmithKline Pakistan Ltd KAR:GLAXO
92 GF Score
Price ₨370.25
GF Value ₨324.26
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pakistan EPS (Basic)?

GlaxoSmithKline Pakistan KAR:GLAXO +1.66% 92 EPS (Basic) is ₨33.01 as of Mar. 2026. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.26 (Modestly Overvalued). The stock has 1 warning sign investors should review.

GlaxoSmithKline Pakistan's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₨8.20. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₨33.01.

GlaxoSmithKline Pakistan's EPS (Diluted) for the three months ended in Mar. 2026 was ₨8.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₨33.01.

GlaxoSmithKline Pakistan's EPS without NRI for the three months ended in Mar. 2026 was ₨8.17. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 32.96.

During the past 12 months, GlaxoSmithKline Pakistan's average EPS without NRIGrowth Rate was 29.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 60.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 15.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, GlaxoSmithKline Pakistan's highest 3-Year average EPS without NRI Growth Rate was 60.40% per year. The lowest was -43.00% per year. And the median was 9.00% per year.

GlaxoSmithKline Pakistan  (KAR:GLAXO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

GlaxoSmithKline Pakistan EPS (Basic) Related Terms

GlaxoSmithKline Pakistan EPS (Basic) Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pakistan's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pakistan EPS (Basic) Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.81 7.73 1.68 20.52 31.48

GlaxoSmithKline Pakistan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.68 6.50 6.40 11.91 8.20
KAR:GLAXO
92GF Score
GlaxoSmithKline Pakistan Ltd KAR:GLAXO
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pakistan EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

GlaxoSmithKline Pakistan's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(10025.315-0)/318.467
=31.48

GlaxoSmithKline Pakistan's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(2610.704-0)/318.467
=8.20

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨33.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₨33.01 mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a EPS (Basic) of ₨33.01 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on GlaxoSmithKline Pakistan and its competitors.
Is GlaxoSmithKline Pakistan's EPS (Basic) too high?
GlaxoSmithKline Pakistan's current EPS (Basic) is ₨33.01. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's EPS (Basic) compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's EPS (Basic) of ₨33.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on GlaxoSmithKline Pakistan and its competitors. GlaxoSmithKline Pakistan's current EPS (Basic) is ₨33.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current EPS (Basic) is ₨33.01. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current EPS (Basic) is ₨33.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued. The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26. GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.

Key valuation signals for KAR:GLAXO:

  • EPS (Basic): ₨33.01
  • GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pakistan Business Description

Address 35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score

Get the complete analysis for KAR:GLAXO

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨370.25
Price
₨324.26
GF Value